|
|
214 Carnegie Center, Suite 100 Princeton, NJ 08540 USA phone:609-514-4744 fax:609-514-0502
|
|
| Symbol |
DSCI |
| Exchange |
OTC |
| Founded |
1984 |
| Employees |
163 |
|
|
| www.dermasciences.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| $50 Million specialty medical device and pharmaceutical company focused on advanced wound care. |
 |
| Management |
Edward J. Quilty, Chairman, Chief Exec. Officer and
President; John E. Yetter, Chief Financial Officer, Principal
Accounting Officer and VP; Barry Wolfenson, Exec. VP Global Marketing & Business Development. |
| |
|
|
|
|
|
|
|
| Keywords |
| caregivers, leptospermum, pneumatic, lymphedema, antimicrobial |
|
|
|
| Description |
Derma Sciences, Inc. is a specialty medical device / pharmaceutical company focused on wound care. The company focuses on three primary areas:
Advanced Wound Care - Several newly-launched proprietary dressings along with a full line of products for chronic wounds and burns. Approximately 17% of current total revenue, expecting to grow to 28% of total revenue in 2010. This is our high-growth, high-margins area of concentration.
Drug Development - Drug candidate DSC127 is in a Phase II study on Diabetic Foot Ulcer healing. Enrollment is expected to be completed within Q3 2010, with initial key efficacy results to be reported towards the end of Q4 2010.
Basic Wound Care - Includes both branded and private-label/OEM bandages, gauze-based dressings, wound closure strips, and first aid products. This is Derma's core business. Currently generating over 80% of current total revenue. The cash flow from this portion of our business funds our advanced wound care and drug development programs.
Derma Sciences' products are marketed to wound care centers, long-term care facilities, hospitals, physicians' offices, clinics, home health care agencies and other health care institutions, as well as pharmacies on the retail side of the business. |
 |
| Products / Services |
The company offers wound closure strips, nasal tube fasteners, and catheter fasteners to doctors, clinics, nursing homes, hospitals, and other institutions; and barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils, and moisturizers to nursing homes, hospitals, and home healthcare agencies.
|
 |
| Technology / Differentiation |
| The company offers advanced/active wound care products comprising Medihoney dressings to manage non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; Bioguard dressings for prophylactic use to prevent hospital or community acquired infections through wound sites; Algicell Ag, an antimicrobial dressing; Xtrasorb dressings that convert fluid within the dressing to a gel and locks the exudates into the dressing; TCC-EZ, a dressing system for the management of diabetic foot ulcers; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and Dermagran products. . In addition, Further, it involves in developing DSC127, an angiotensin analog for use in wound healing and scar reduction. The company serves wound care centers, long-term care facilities, hospitals, home healthcare agencies, physiciansÂ’ offices, and closed door pharmacies. |
 |
| Market / Customers |
The company sells its products primarily through independent distributors in the United States, Canada, and internationally.
|
 |
| Status |
| DSC127 is a patented analog of a naturally occurring peptide, Angiotensin. In multiple pre-clinical animal models, it has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization. Additionally, histological examination has shown that DSC127 accelerated collagen deposition six-fold. All these help to accelerate dermal tissue repair. The drug is currently in a Phase II Diabetic Ulcer study. |
 |
|
|
|
|
|
|